Menu
Back toAgenda
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
By clicking SUBSCRIBE, you are agreeing to our Privacy Policy.
17th DIA Japan Annual Meeting 2020
All prices are exclusive of 10% Japanese consumption tax
Agenda
Day 1
- — LS01 Opening
- — OS01 Special Session 1: Overcoming Drug-Induced Suffering
- — OS02 Special Session 2: International Contribution to Drug Development
- — OS03 Real World Data: Concrete Utilization Examples and Issues
- — OS04 Aiming for Further Acceleration of Gene Therapy Product Development
- — OS05 Beyond the Artificial Intelligence (AI) Revolution: What Does the Future Hold for the Healthcare and Pharmaceutical Industries?
- — OS06 Challenge of Incorporating Patient Perspective in Drug Development: Lessons Learned from “System of Patient Engagement inRregulatory Review” by US Food and Drug Administration/European Medicines Agency
- — OS07 Hot Topics in Using RWD in Drug Development
- — OS08 What’s Needed to Transform Flow of Information in Clinical Development
- — OS09 Applying Quality Management Principles from Engineering to Clinical Trials
- — OS10 Considerations for Utilizing Wearable Sensors in Clinical Research
- — OS12 Changes Accelerated by Innovation: Clinical Operation & Data Management
- — OS13 The “Where, What, and How” of Patient Needs for Clinical Trial information from the Standpoint of Individual Stakeholders: Study Participant Opinions and Study Site Updates
- — OS14 Implementing Revision of Pharmaceutical Affairs Law: Perspectives on Current and Future eLabeling
- — OS15 The Additional Pharmacovigilance Plan: Role in Japan
- — OS16 What is the Quality of Real World Evidence?
- — LS02 Quantitative Decision Making in Drug Development
- — LS03 Realization of Personalized Medicine through Reverse Translational Research
- — SLS01 ICH 30th Anniversary: Summary of 30 Years and Future Prospects with the Role of Japan
- — LS04 What Covid-19 Has Brought to Us
- — LS05 Student Session: Protocol Development in Oncology Clinical Trials
- — SLS02 Next Generation Leadership for Successful Future
- — LS06 How Do We Collaborate with Current Patients for Future Patients in Drug Development?
- — SLS03 ICH Anniversary: Summary of 30 Years and Future Prospects in Q Area with the Role of Japan
- — LS07 Overcome Challenges in Complex Drug Development: Let’s Learn More About Program Management
- — SLS04 Scientific Benefit-Risk Management and Communication for the Future
- — SLS05 ICH Anniversary: Summary of 30 Years and Future Prospects in S Area with Role of Japan
- — LS08 Young Professionals Exchange Networking Session
Day 2
- — LS09 Driving Toward Further Operational Efficiency and Innovation in Clinical Trials
- — SLS06 New Approaches for Further Improvement in Knowledge Management
- — SLS07 Applying “Training / Learning Innovation” to Clinical Development Projects
- — SLS08 ICH Anniversary: Summary of 30 Years and Future Prospects in E Area with Role of Japan
- — LS10 ICH M11: Clinical Electronic Structured Harmonized Protocol
- — LS11 Keynote Address: Patient-Focused Drug Development
- — SLS09 How Do Quality Risk Management and Risk-Based Monitoring Work Together? Gaps Between Ideal and Actual Experience During COVID-19
- — SLS10 Status and Challenges of Regulatory Decision Making in Development Using Model Informed Drug Development
- — SLSx09
- — LS12 Creating an Insightful Patient Journey Map On-Site: Let’s look at and Feel The Patients’ Voice Together and Think about What We Can Do! (part 1)
- — LS13 Let’s Broaden Young Peoples’ Horizons from the Multidisciplinary Perspective
- — SLS11 How Can industry Play a Role through Publications to Elevate Patient Voice?
- — SLS12 ICH Anniversary: Summary of 30 years and Future Prospects in M Area with Role of Japan
- — LS14 Creating an Insightful Patient Journey Map On-Site: Let’s look at and feel the patients’ voice together and think about what we can do! (part 2)
- — LS15 Career Development in the New Healthcare Era
- — LS16 Current Status and Future of Digital Therapeutics (DTx): How DTx Are Developed and Penetrate Medical Care
- — SLS13 Impact of Patient Engagement Initiatives in Clinical Trial Design and Execution
- — SLS14 WHAT’S NEW? Risk Communication and Pharmaceutical Information in the Digital Era in Japan, Europe, and the US
- — SLS15 Digital Transformation of Medical Information in Japan from Development to Post-Marketing
- — SLS16
- — SLS17 Current Status of Drug Development and Current Challenges for Clinical Trials and Regulations in China
- — LS17 Special Chat Session
Day 3
- — LS18 Global Oncology Development – 2nd
- — LS19 Data Reliability and Quality for Post-Marketing Database Study
- — SLS18 Joining Global Advanced Clinical Trials: Japan’s Perspective and the Kobe Initiative
- — SLS19 Innovative Engagement: Talk with External Expert in Medical Affairs Activity
- — LS20 New Phase in Combatting Antimicrobial Resistance (AMR)
- — SLS20 Opportunity for International Harmonization of Implementing Early Access to Pharmaceuticals
- — SLS21 “Where, What, and How” of Clinical Trial Information Required by Patients: Disclosure of Investigator Site Name and Clinical Trial Results
- — SLS22 Patient-Centric Approach to Clinical Research: Challenges to Improving Efficiency and Quality
- — LS21 Clinical Trial Innovation: Learning from Case Study and Accelerating Adaptation in Japan
- — SLS23 How to Promote Use of Centralized IRB in Clinical Trials
- — SLS24 “Rule of Rules” for Development Tool Qualification
- — LS22 Real Operations in Regenerative Medicine Product Clinical Trials
- — LS23 DIAmond Session 2: PMDA Town Hall
- — LS24 Utilization of “Pharmaceuticals for Specific Use” for Pediatric Drug Development
- — SLS26 Operational Innovation in Medical Affairs for Improved Patient Outcomes
- — SLS27 DIAmond Session 3: Beyond Innovation – What is Future Healthcare?
- — SLS28 Recent Advances in Pharmacovigilance: Machine Learning and Statistical Pattern Discovery Case Studies from Around the World
- — SLS29 Improving Sponsor Clinical Trial Processes by Utilizing the Voice of Clinical Study Sites
- — LS25 Closing Remarks
